{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-030400","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.006318+00:00","generated_at":"2026-05-17T14:25:04.539742+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Grace Therapeutics reports Q1 net loss $3.4M; submits GTx-104 NDA to FDA","bullets":["Net loss $3.4M ($0.21/sh) vs $2.6M ($0.24/sh) in prior-year quarter; R&D down $1.8M to $0.9M.","Submitted NDA to FDA for GTx-104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage; based on positive STRIVE-ON Phase 3 trial.","STRIVE-ON met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; 54% patients had ≥95% relative dose intensity.","Cash and equivalents $20.0M; potential warrant exercises of $22.6M ($7.6M + $15.0M) could extend runway into Q2 2027.","Deprioritized GTx-102 and GTx-101 to focus on GTx-104; may license or sell those assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-030400","json":"https://secwatch.observer/filing/0001140361-25-030400.json","markdown":"https://secwatch.observer/filing/0001140361-25-030400.md","text":"https://secwatch.observer/filing/0001140361-25-030400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/0001140361-25-030400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000114036125030400/ef20053073_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:25:04.539742+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}